Mirna Therapeutics (MIRN) Posts Wider Q3 Loss

Mirna Therapeutics (NASDAQ: MIRN) reported Q3 EPS of ($82.16), versus ($73.73) reported last year. The results included non-cash, stock-based compensation charges of approximately $210,000 in the three months ended September 30, 2015 and approximately $101,000 in the same period in 2014.

For earnings history and earnings-related data on Mirna Therapeutics (MIRN) click here.

You May Also Be Interested In

• Karyopharm Therapeutics (KPTI) Misses Q2 EPS by $1.01, Beats on Revenue; Offers FY26 Revenue Guidance
• BK Technologies (BKTI) Tops Q2 EPS by 11c
• Stratasys (SSYS) Tops Q2 EPS by 2c ;; Offers Guidance